ChemGenex Pharmaceuticals to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A.
October 30, 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today that Greg Collier, Ph.D., chief executive officer and managing director, will present a company overview at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. The presentation will take place at 4:05 pm ET on Monday, November 5th, 2007, at the New York Palace Hotel in New York City.
The presentation will be webcast live and may be accessed at www.wsw.com/webcast/rrshq12/cxsp. An archived version will be available at the same location for 90 days following the presentation.
About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes and obesity. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex’s lead compound, omacetaxine mepesuccinate (formerly known as Ceflatonin®), is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) and amonafide dihydrochloride (formerly known as Quinamed®) is in phase 2 clinical development for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes and obesity programs, several of which have been partnered with international pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP".
Company Contacts
| Dr. Greg Collier (CEO and Managing Director) |
Australia +61 3 5227 2752
USA +1 650 474 9800 XT 103 |
| Dr. Dennis Brown (President and Director) |
USA +1 650 474 9800 XT 108
Australia +61 3 5227 2703 |
Investor Relations – Australia
| Sabrina Antoniou (Blueprint Lifescience Group) |
Cell: +61 (0) 400 788 277
Email: santoniou@bplifescience.com |
Investor Relations – USA
| Susan Ferris (Blueprint Lifescience Group) |
Tel: +1 415 602 6600
Email: sferris@bplifescience.com |
Media Relations
| Daniella Goldberg (Buchan Communications) |
Tel: +61 2 9237 2803
Cell: +61 (0) 416 211 067
Email: dgoldberg@bcg.com.au |
Safe Harbor Statement
Certain statements made herein that use the words “estimate”, “project”, “intend”, “expect”, “believe”, and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company’s technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company’s technology, the market for the company’s products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management’s current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.
